

22 February 2021

Market Announcements Office  
ASX Limited  
Level 4, North Tower, Rialto  
525 Collins Street  
Melbourne VIC 3000

*Electronic Lodgement via ASX Online*

**Pro Medicus Limited (PME) – sell down by Sam Hupert as Founder**

The Company has been informed that Sam Hupert has sold 1,000,000 ordinary shares in the capital of the Company.

As a consequence, the remaining holdings of Sam Hupert are 27,137,660 ordinary shares in the capital of the Company, representing approximately 26.04% of the issued share capital of the Company.



**Clayton Hatch**  
Company Secretary  
Pro Medicus Limited

22 February 2021

Peter Kempen  
Chairman  
Pro Medicus Limited  
450 Swan Street  
Richmond VIC 3121

Clayton Hatch  
Company Secretary  
Pro Medicus Limited  
450 Swan Street  
Richmond VIC 3121

Dear Peter & Clayton,

**Reduction of shareholding in Pro Medicus Limited (PME)**

I am writing to inform you that I have sold 1,000,000 of my shares in PME in the last few days.

My shareholding in PME on completion of the sale will be approximately 26.04% and I do not intend to sell any further shares in PME in the foreseeable future.

Yours faithfully,



**Sam Hupert**  
CEO and Co-Founder  
Pro Medicus Limited

22 February 2021

Market Announcements Office  
ASX Limited  
Level 4, North Tower, Rialto  
525 Collins Street  
Melbourne VIC 3000

*Electronic Lodgement via ASX Online*

**Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the Act)**

Pro Medicus Limited (ASX Code: PME) (**Company**) refers to the announcement on 19 February 2021 in relation to the sale by Dr Sam Hupert of 1,000,000 shares in the Company.

This notice is given by the Company under section 708A(5)(e) of the Act (as modified by ASIC Instrument 2016/81).

The Company advises that:

- (a) Dr Hupert sold the relevant securities in the Company without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (ii) section 674 of the Act; and
- (c) as at the date of this notice, there is no "excluded information" for the purposes of subsections 708A(7) or (8) of the Act.

Yours faithfully,



**Clayton Hatch**  
Company Secretary  
Pro Medicus Limited

The Manager  
Company Announcements Office  
ASX Limited  
Level 4, North Tower, Rialto  
525 Collins Street  
Melbourne VIC 3000

22 February 2021

Dear Sir/Madam

**Pro Medicus Limited (ASX: PME) Sale offers within 12 months after controller sales**

For the purposes of section 708A(5) and (6) of the *Corporations Act 2001* (Cth) (**Act**), as modified by ASIC Corporations (Sale Offers By Controllers) Instrument 2016/81, Sam Hupert (**Vendor**) gives notice under section 708A(5)(e) of the Act of the following details:

- (a) On 18 February 2021, the vendor executed the sale of 1,000,000 fully paid ordinary shares (**Sale Shares**) in the issued capital of Pro Medicus Limited (**PME**) to a range of institutional investors;
- (b) the Vendor, as a controller of PME for the purposes of the Act at the date of the sale, sold the Sale Shares without disclosure to investors under Part 6D.2 of the Act;
- (c) as far as the Vendor is aware, as at the date of this notice, PME has complied with the provisions of Chapter 2M as they apply to PME and section 674 of the Act; and
- (d) the Vendor is not aware of any information that may be “excluded information” for the purposes of section 708A(7) or (8) of the Act, as at the date of this notice.

Issued by



**Sam Hupert**  
CEO and Co-Founder  
Pro Medicus Limited